Biotechnology company and drug delivery platform
innovator Lexaria Bioscience
Corp. (CSE: LXX) (OTC: LXRP)today announced that Health Canada has issued
cannabis Research and Development (“R&D”) license LIC-7NONT76UNW-2019 to
its subsidiary, Lexaria CanPharm ULC. According to the update, the license,
which carries a four-year term unless renewed, is effective immediately and
will allow one of the country’s newest and most advanced formulation
laboratories to conduct extensive investigatory work in THC and CBD delivery
using optimized, proprietary formulations and techniques. The purpose-built
laboratory is permitted at local and federal levels and fully outfitted to
produce DehydraTECH(TM) infusions and includes two different methodologies by
which the company can create nano-sized molecules when deemed beneficial.
“Receipt of our R&D License from Health Canada will allow us to implement
and complete investigatory studies significantly more rapidly now, than at any
previous time in our Company’s history,” Lexaria President and Chief Scientist
John Docherty said in the news release. “This license will greatly enhance our
ability to work with cannabis Licensed Producers to perform work in-house on
customized formulations that could benefit each of Canada’s licensed cannabis
companies.”
To view the full press releases, visit http://ibn.fm/f8X80
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. has developed and out-licenses its
disruptive delivery technology that promotes healthier ingestion methods, lower
overall dosing and higher effectiveness of lipophilic active molecules. Lexaria
has multiple patents pending in over 40 countries around the world and has
patents granted in the USA and in Australia for utilization of its
DehydraTECH(TM) delivery technology. Lexaria’s technology provides increases in
intestinal absorption rates; more rapid delivery to the bloodstream; and
important taste-masking benefits, for orally administered bioactive molecules
including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs
(NSAIDs), nicotine and other molecules. For more information, visit the
company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
